Which laboratory tests should be monitored in a patient with a history of testicular cancer who underwent orchiectomy 15 years ago and now has low testosterone?

Laboratory Monitoring in Testicular Cancer Survivors with Low Testosterone

In a testicular cancer survivor 15 years post-orchiectomy with low testosterone, you should monitor total testosterone, free testosterone, LH, FSH, complete blood count (hemoglobin/hematocrit), lipid panel, PSA, and metabolic parameters every 3-6 months initially if testosterone replacement is initiated, then annually thereafter.

Cancer Surveillance Labs

At 15 years post-treatment, routine tumor marker surveillance is no longer indicated:

• Tumor markers (AFP, β-HCG, LDH) are NOT routinely needed at this timepoint, as post-chemotherapy patients require clinical review and tumor markers only as clinically indicated beyond 5 years 1
• Tumor markers are primarily used during active treatment and early follow-up (first 5 years), with monitoring 2-monthly for year 1,3-monthly for year 2, then 6-monthly to 5 years 1

Hypogonadism Assessment Labs

Baseline hormonal evaluation should include:

• Total testosterone – measured using a CDC-certified assay or accuracy-based standardized method 2
• Free testosterone – men with low free testosterone have sexual and physical symptoms consistent with testosterone deficiency regardless of total testosterone 2
• Luteinizing hormone (LH) – testicular cancer survivors show persistently elevated LH levels even decades after treatment 3, 4
• Follicle-stimulating hormone (FSH) – FSH levels are markedly elevated in testicular cancer survivors, with odds ratios of 18.9 after radiotherapy and 14.2 after chemotherapy 3

The prevalence of biochemical hypogonadism increases dramatically over time: from 12% at median 11 years to 41% at 27 years post-diagnosis in testicular cancer survivors, compared to only 5% to 11% in age-matched controls 5. At 15 years post-orchiectomy, this patient is in the high-risk window for developing hypogonadism.

If Testosterone Replacement Therapy is Initiated

Mandatory monitoring parameters include:

Hematologic Monitoring

• Hemoglobin and hematocrit every 3 months initially, then every 6 months – erythrocytosis occurs in 15-44% of men on testosterone therapy and is the most common serious adverse event 6
• Hold testosterone if hematocrit exceeds 50% and consider therapeutic phlebotomy if hematocrit reaches 54% 6
• Iron studies (ferritin) – iron deficiency may mask erythrocytosis; defer iron supplementation until hematocrit is controlled 6

Hormonal Monitoring

• Total and free testosterone levels every 3-6 months to maintain mid-normal range (400-600 ng/dL total testosterone) 6
• Estradiol levels – elevated estradiol (>39 pg/mL) is linked to higher erythrocytosis risk 6
• SHBG – low SHBG increases free testosterone availability and erythrocytosis risk 6

Cardiovascular & Metabolic Monitoring

• Lipid panel – testicular cancer survivors often have dyslipidemia requiring statin therapy 6
• Blood pressure at each visit 6
• Fasting glucose or HbA1c – testosterone therapy affects metabolic parameters 2

Prostate Monitoring

• PSA and digital rectal exam every 3-6 months initially, then annually 6
• Consider prostate biopsy if PSA rises >1.0 ng/mL within 6 months or >0.4 ng/mL/year thereafter 6

Additional Considerations

Screen for associated conditions:

• Morning cortisol – low cortisol warrants ACTH stimulation testing to exclude adrenal insufficiency, which can coexist 6
• Sleep apnea symptoms at each visit, as testosterone therapy may worsen obstructive sleep apnea 6
• Bone mineral density – consider baseline and periodic assessment, especially if hypogonadism has been longstanding 7

Common Pitfalls to Avoid

• Do not assume cancer recurrence without clinical indication – at 15 years post-treatment with excellent cure rates (>99% for stage I disease), routine tumor marker surveillance is not evidence-based 8
• Do not ignore elevated hematocrit – this is the most frequent serious complication requiring dose adjustment or temporary discontinuation 6
• Do not supplement iron until erythrocytosis is controlled – iron repletion may further elevate hematocrit 6
• Do not overlook treatment-related risk – the probability of hypogonadism is threefold higher in testicular cancer survivors than controls at 30 years post-diagnosis, with risk correlating to treatment intensity (radiotherapy or chemotherapy > surgery alone) 5, 3
• Consider transdermal over injectable testosterone – injectable formulations have markedly higher erythrocytosis rates (43.8% vs 2.8-15.4% for transdermal) 6